QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s European Society for Medical Oncology (ESMO) congress in Copenhagen.
Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte
